menu menu_open
Brasil
home Sumário navigate_before Anterior Atual Seguinte navigate_next
home Sumário
Historical Notes • Arq. Neuro-Psiquiatr. 79 (10) • Oct 2021 • https://doi.org/10.1590/0004-282X-ANP-2020-0574 linkcopy

Open-access A journey through the history of Neurogenetics

Uma jornada pela história da Neurogenética

AuthorshipSCIMAGO INSTITUTIONS RANKINGS

    ABSTRACT

    Since the late 19th century, when several inherited neurological disorders were described, the close relationship between Neurology and heredity were well documented by several authors in a pre-genetic era. The term Neurogenetics came to integrate two large sciences and clinical practices: Neurology and Genetics. Neurogenetics is the emerging field that studies the correlation between genetic code and the development and function of the nervous system, including behavioral traits, personality and neurological diseases. In this historical note, a timeline shows the main events and contributors since the first reports of neurogenetic diseases until the current days. In the recent years, neurologists are experiencing much broader use of new genetic diagnosis techniques in clinical practice. Thus, new challenges are arising in diagnostic approach, ethical considerations, and therapeutic options. This article aims to summarize the main historical hallmarks of Neurogenetics, from the pre-DNA era to the present, and the future directions of the field.

    Keywords: Genetic Diseases, Inborn; History; Neurology; Genetics

    RESUMO

    Desde o final do século XIX, quando diversas doenças neurológicas hereditárias foram descritas, a associação entre neurologia e hereditariedade foi bem documentada por vários autores na era pré-genética. O termo Neurogenética integra dois campos da ciência e da prática clínica: Neurologia e Genética. A Neurogenética é o campo que estuda a correlação entre o código genético e o desenvolvimento e a função do sistema nervoso, incluindo comportamento, personalidade e doenças neurológicas. Nesta nota histórica, a linha do tempo mostra os principais eventos e pesquisadores desde os primeiros relatos de doenças neurogenéticas até os dias atuais. Recentemente, neurologistas estão se deparando com maior uso de técnicas diagnósticas genéticas na prática clínica; portanto, novos desafios surgem na abordagem diagnóstica, nas considerações éticas e na terapêutica. Este artigo almeja resumir os principais marcos históricos da Neurogenética, desde a era pré-DNA até o presente, e os caminhos futuros desse campo de conhecimento.

    Palavras-chave: Doenças Genéticas Inatas; História; Neurologia; Genética

    Since the birth of modern Neurology in the late 19th century, many physicians noticed the importance of family history in the diagnostic approach of neurological disorders. At that time, studies in the Genetics area tried to better understand the mechanisms involved in inherited diseases.

    The term Neurogenetics integrates two areas: Neurology and Genetics. It formally started in mid-1960s when Seymour Benzer developed experiments with Drosophila, intending to prove that animal behaviors could be directed by single gene mutations (Figure 1). Benzer’s research also became the cornerstone to the study of neurological diseases in humans, particularly, neurodegenerative disorders1,2.

    Figure 1.
    Seymour Benzer, considered the father of Neurogenetics, in his office at Caltech in 1974 with a big model of Drosophila.

    This article aims to summarize the major historical hallmarks in the field of neurogenetics, from the pre-DNA era to the present, and the future directions of the field.

    THE FIRST NEUROGENETIC DISEASES

    Gregor Mendel, the “father of modern Genetics”, is acknowledged for his experiments with pea plants hybridization, published in 1866, in which he synthetized the laws of inheritance. His work, though, remained obscure until 1900, when it was rediscovered3. However, even before Mendel, physicians had already recognized inherited patterns of neurological diseases.

    In 1863, Nikolaus Friedreich described a hereditary juvenile-onset ataxia with sensory loss, cardiomyopathy, scoliosis and pes cavus. More than a century later the genetic basis of Friedreich`s ataxia was described: guanine-adenosine-adenosine (GAA) trinucleotide repeat4,5. In 1872, George Huntington wrote the essay “On Chorea”, where he described the hereditary nature, neuropsychiatric symptoms and adult-onset. Huntington’s disease is caused by expansion in trinucleotide cytosine-adenosine-guanine (CAG) repeat6,7.

    In 1880, the first depiction of hereditary spastic paraplegia was published by Ernst Adolf Gustav Gottfried von Strümpell. Maurice Lorrain, in 1888, contributed with anatomical description. Since then, more than 80 loci have been related to hereditary spastic paraplegia8. In 1886, the hereditary sensorimotor neuropathy was described independently by two groups: in France, Jean Martin Charcot and Pierre Marie published a progressive muscular atrophy, with child and juvenile onset, distal lower limb atrophy and pes cavus. Later, Henry Tooth reported five patients with progressive muscular atrophy9.

    Pierre Marie, in 1893, reviewed a series of ataxia with adult onset, oculomotor abnormalities and autosomal dominant inheritance. Later, Joseph Jules Dejerine and André-Thomas suggested the term olivopontocerebellar atrophy (OPCA) to describe this disease. Through the 20th century, several disorders were recognized under the broad phenotype of Marie’s ataxia, most of them encompassed in the group of spinocerebellar ataxias (SCA). Currently, more than 40 gene loci causing SCAs have been described10,11,12.

    DNA DISCOVERY AND MOVING ON

    In the 1910s, Thomas Morgan proved that genes resided in certain locations of chromosomes. In 1944, Oswald Avery, Colin MacLeod and Maclyn McCarty concluded that DNA held the genetic information. In 1953, James Watson and Francis Crick demonstrated the DNA structure13. In the late 1950s, Seymour Benzer showed that a mutation could occur in multiple sites within the genetic code, originating the notion of “point mutation”14. In the 1970s, Fredrick Sanger developed the first widely used method of DNA sequencing relying on nucleotide-specific chain-termination inhibitors13.

    By 1980s, advances in molecular biology techniques, especially reverse genetics and recombinant DNA, allowed the identification of causal association between DNA variants and diseases through linkage analysis: the knowledge that DNA sequences that are closer in the chromosome tend to segregate together during meiosis have allowed the construction of linkage maps, using recombinant DNA probes, which ultimately led to identification the locus of Huntington’s disease in 1983, and the discovery of the gene for Duchene muscular dystrophy in 1987 without prior knowledge of the defective protein15.

    The 1990s were marked by the discovery of di-, tri and tetranucleotide repeats (microsatellites) which are highly polymorphic among healthy people and the ease of genotyping these repeats with polymerase chain reaction (PCR). These innovations led to the discovery of several specific genes related to classical neurological diseases, such as Charcot-Marie-Tooth’s, amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s, spinocerebellar ataxias and fragile X syndrome16.

    More recently, several names participated on extremely relevant works around neurogenetics. Of note, Anita Elizabeth Harding participated on the discovery of the mitochondrial DNA mutation in human disease and the concept of tissue heteroplasmy of mutant mitochondrial DNA.

    In the 2000s, the integration of phenotypic mapping and sequencing data with new computational resources enabled the recognition of a larger number of hereditary disorders. In this same decade, the Human Genome Project (1990-2003) determined the entire sequence of base pairs that make up human DNA. By 2010, with the next-generation sequencing (NGS) development, whole genome sequence could be analyzed in few weeks17. Figure 2 is a timeline that shows the main events and contributors since the first reports of neurogenetic diseases till the current days.

    Figure 2.
    Timeline with the main events and contributors since the first reports of neurogenetic diseases until the current days.

    In Brazil, many scientists and clinicians have participated on the description of neurogenetic diseases during the last decades. Some Brazilian institutions, such as the Centro de Estudos do Genoma Humano e Células-Tronco from the Universidade de São Paulo, have played an important role in the studies of neurogenetic diseases.

    THE ERA OF EXOME SEQUENCING

    The NGS, released in the mid-2000s, offered an improvement in processing the genetic investigation. Through the selection of regions of interest, whole exome sequencing (WES) allowed the successful identification of several monogenic diseases18. WES and whole genome sequencing (WGS) allowed the accurate identification of single nucleotide variants and small insertions or deletions (InDels). For larger InDels, copy-number variation and genomic rearrangements, microarray, and MLPA techniques are more accurate19.

    FUTURE DIRECTIONS: WHAT IS NEXT?

    With NGS development, a new modus operandi is arising in diagnostic approach: for instance, WES turns out to be a better diagnostic tool for leukodystrophies diagnostic assessment, allowing more precise, faster, and less costly approach when compared to the traditional biochemical laboratorial investigation. This rapid evolution of technology will demand a continuous update in data interpretation of clinical and NGS information, and, consequentially, genetic counseling19.

    Furthermore, there are ethical dilemmas to point out: genetic testing in asymptomatic individuals and the psychological side effects of the diagnosis (e.g., HD diagnosis in pre-symptomatic patient), confidentiality of genetic information, genetic testing in children, whose autonomy is delegated to the parents, and prenatal testing of embryos are issues that need to be carefully considered in our daily practice, as the cost of genetic test drop and more people can perform the exams.

    For a long time, symptomatic treatment was the only option for neurogenetic disorders. Recently, the scenario has been changing as specific disease-modifying drugs for neurogenetic conditions have been approved. Several biochemical therapies were developed for inborn errors of metabolism (e.g., miglustat to treat Niemann-Pick type C, and migalastat for Fabry disease); antisense oligonucleotides (ASO) and gene therapy have an increasing importance, since clinical trials to treat polyglutamine disorders, such as HD and SCA 2, are being held, and antisense therapy for Duchenne muscular dystrophy (DMD) has been aproved18. Moreover, CRISPR-cas9 genome editing technology has emerged as a perspective for the treatment of neurogenetic disorders20.

    References

    Publication Dates

    • Publication in this collection
      20 Sept 2021
    • Date of issue
      Oct 2021

    History

    • Received
      08 Dec 2020
    • Reviewed
      14 Mar 2021
    • Accepted
      28 Mar 2021
    Creative Common - by 4.0
    This is an open-access article distributed under the terms of the Creative Commons Attribution License
    vertical_align_top file_download show_chart
    location_on
    Academia Brasileira de Neurologia - ABNEURO R. Vergueiro, 1353 sl.1404 - Ed. Top Towers Offices Torre Norte, 04101-000 São Paulo SP Brazil, Tel.: +55 11 5084-9463 | +55 11 5083-3876 - São Paulo - SP - Brazil
    E-mail: revista.arquivos@abneuro.org
    rss_feed Acompanhe os números deste periódico no seu leitor de RSS
    Acessibilidade / Reportar erro